Compare · ADMS vs MYOK
ADMS vs MYOK
Side-by-side comparison of Adamas Pharmaceuticals, Inc. (ADMS) and MyoKardia, Inc. (MYOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMS and MYOK operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ADMS carries a market cap of $373.6M.
- ADMS has more recent analyst coverage (5 ratings vs 0 for MYOK).
- Company
- Adamas Pharmaceuticals, Inc.
- MyoKardia, Inc.
- Price
- $8.21+0.61%
- -
- Market cap
- $373.6M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Latest ADMS
- SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)
- SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.
- SEC Form 4: Bigham Michael closing all direct ownership in the company
- SEC Form 4: Mahoney David L closing all direct ownership in the company
- SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Mcfarlane Neil F. was granted 75,000 shares, closing all direct ownership in the company
- SEC Form 4: Ericson William W. closing all direct ownership in the company
- SEC Form 4: Shreedhar Vijay was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Papapetropoulos Spyridon closing all direct ownership in the company
Latest MYOK
- FDA Approval for CAMZYOS issued to MYOKARDIA INC
- MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
- MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
- MyoKardia Reports Third Quarter 2020 Financial Results
- Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
- MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
- Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
- MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
- SHAREHOLDER ALERT: WeissLaw LLP Reminds MYOK, PTI, BMCH and GHIV Shareholders About Its Ongoing Investigations